381 related articles for article (PubMed ID: 31482461)
21. Targeting of the kynurenic acid across the blood-brain barrier by core-shell nanoparticles.
Varga N; Csapó E; Majláth Z; Ilisz I; Krizbai IA; Wilhelm I; Knapp L; Toldi J; Vécsei L; Dékány I
Eur J Pharm Sci; 2016 Apr; 86():67-74. PubMed ID: 26924227
[TBL] [Abstract][Full Text] [Related]
22. Nanoparticle transport across the blood brain barrier.
Grabrucker AM; Ruozi B; Belletti D; Pederzoli F; Forni F; Vandelli MA; Tosi G
Tissue Barriers; 2016; 4(1):e1153568. PubMed ID: 27141426
[TBL] [Abstract][Full Text] [Related]
23. Current Strategies for Brain Drug Delivery.
Dong X
Theranostics; 2018; 8(6):1481-1493. PubMed ID: 29556336
[TBL] [Abstract][Full Text] [Related]
24. Crossing the Blood-Brain Barrier: A Review on Drug Delivery Strategies for Treatment of the Central Nervous System Diseases.
Mansor NI; Nordin N; Mohamed F; Ling KH; Rosli R; Hassan Z
Curr Drug Deliv; 2019; 16(8):698-711. PubMed ID: 31456519
[TBL] [Abstract][Full Text] [Related]
25. Donepezil loaded PLGA-b-PEG nanoparticles: their ability to induce destabilization of amyloid fibrils and to cross blood brain barrier in vitro.
Baysal I; Ucar G; Gultekinoglu M; Ulubayram K; Yabanoglu-Ciftci S
J Neural Transm (Vienna); 2017 Jan; 124(1):33-45. PubMed ID: 26911385
[TBL] [Abstract][Full Text] [Related]
26. Feasibility Study of the Permeability and Uptake of Mesoporous Silica Nanoparticles across the Blood-Brain Barrier.
Baghirov H; Karaman D; Viitala T; Duchanoy A; Lou YR; Mamaeva V; Pryazhnikov E; Khiroug L; de Lange Davies C; Sahlgren C; Rosenholm JM
PLoS One; 2016; 11(8):e0160705. PubMed ID: 27547955
[TBL] [Abstract][Full Text] [Related]
27. Overcoming the blood-brain barrier for delivering drugs into the brain by using adenosine receptor nanoagonist.
Gao X; Qian J; Zheng S; Changyi Y; Zhang J; Ju S; Zhu J; Li C
ACS Nano; 2014 Apr; 8(4):3678-89. PubMed ID: 24673594
[TBL] [Abstract][Full Text] [Related]
28. Nano carriers for drug transport across the blood-brain barrier.
Li X; Tsibouklis J; Weng T; Zhang B; Yin G; Feng G; Cui Y; Savina IN; Mikhalovska LI; Sandeman SR; Howel CA; Mikhalovsky SV
J Drug Target; 2017 Jan; 25(1):17-28. PubMed ID: 27126681
[TBL] [Abstract][Full Text] [Related]
29. Potential use of polymeric nanoparticles for drug delivery across the blood-brain barrier.
Tosi G; Bortot B; Ruozi B; Dolcetta D; Vandelli MA; Forni F; Severini GM
Curr Med Chem; 2013; 20(17):2212-25. PubMed ID: 23458620
[TBL] [Abstract][Full Text] [Related]
30. Essentials and Perspectives of Computational Modelling Assistance for CNS-oriented Nanoparticle-based Drug Delivery Systems.
Kisała J; Hęclik KI; Pogocki K; Pogocki D
Curr Med Chem; 2018; 25(42):5894-5913. PubMed ID: 29768999
[TBL] [Abstract][Full Text] [Related]
31. Targeted brain derived neurotropic factors (BDNF) delivery across the blood-brain barrier for neuro-protection using magnetic nano carriers: an in-vitro study.
Pilakka-Kanthikeel S; Atluri VS; Sagar V; Saxena SK; Nair M
PLoS One; 2013; 8(4):e62241. PubMed ID: 23653680
[TBL] [Abstract][Full Text] [Related]
32. Concepts, technologies, and practices for drug delivery past the blood-brain barrier to the central nervous system.
Crawford L; Rosch J; Putnam D
J Control Release; 2016 Oct; 240():251-266. PubMed ID: 26724368
[TBL] [Abstract][Full Text] [Related]
33. Targeted drug delivery to central nervous system (CNS) for the treatment of neurodegenerative disorders: trends and advances.
Goyal K; Koul V; Singh Y; Anand A
Cent Nerv Syst Agents Med Chem; 2014; 14(1):43-59. PubMed ID: 25360772
[TBL] [Abstract][Full Text] [Related]
34. Targeting nanoparticles across the blood-brain barrier with monoclonal antibodies.
Loureiro JA; Gomes B; Coelho MA; do Carmo Pereira M; Rocha S
Nanomedicine (Lond); 2014 Apr; 9(5):709-22. PubMed ID: 24827845
[TBL] [Abstract][Full Text] [Related]
35. Influence of nanoparticle size on blood-brain barrier penetration and the accumulation of anti-seizure medicines in the brain.
Meng Q; Meng H; Pan Y; Liu J; Li J; Qi Y; Huang Y
J Mater Chem B; 2022 Jan; 10(2):271-281. PubMed ID: 34897348
[TBL] [Abstract][Full Text] [Related]
36. Effects of surface modification of PLGA-PEG-PLGA nanoparticles on loperamide delivery efficiency across the blood-brain barrier.
Chen YC; Hsieh WY; Lee WF; Zeng DT
J Biomater Appl; 2013 Mar; 27(7):909-22. PubMed ID: 22207601
[TBL] [Abstract][Full Text] [Related]
37. Effect of polymer architecture on curcumin encapsulation and release from PEGylated polymer nanoparticles: Toward a drug delivery nano-platform to the CNS.
Rabanel JM; Faivre J; Paka GD; Ramassamy C; Hildgen P; Banquy X
Eur J Pharm Biopharm; 2015 Oct; 96():409-20. PubMed ID: 26409200
[TBL] [Abstract][Full Text] [Related]
38. Noninvasive nanoparticle strategies for brain tumor targeting.
Sun C; Ding Y; Zhou L; Shi D; Sun L; Webster TJ; Shen Y
Nanomedicine; 2017 Nov; 13(8):2605-2621. PubMed ID: 28756093
[TBL] [Abstract][Full Text] [Related]
39. Kinetics of transport of doxorubicin bound to nanoparticles across the blood-brain barrier.
Wohlfart S; Khalansky AS; Gelperina S; Begley D; Kreuter J
J Control Release; 2011 Aug; 154(1):103-7. PubMed ID: 21616104
[TBL] [Abstract][Full Text] [Related]
40. Zebrafish as a visual and dynamic model to study the transport of nanosized drug delivery systems across the biological barriers.
Li Y; Miao X; Chen T; Yi X; Wang R; Zhao H; Lee SM; Wang X; Zheng Y
Colloids Surf B Biointerfaces; 2017 Aug; 156():227-235. PubMed ID: 28544957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
